The Digital Health Care Revolution Picks Up Speed

The excitement about digital health solutions has reached new heights as the market moves toward changes where those solutions are not only wanted, but in many cases needed to help battle costs and improve patient outcomes. The interest in digital health is part of a larger trend that is seeing patients take on more and more responsibility for their own health amid changing perceptions of what is considered a medical device.

The phenomenon goes by several names – digital health, wireless health, connected health, mobile health, etc. – but they all refer to the burgeoning revolution that has the health care industry mesmerized. Investors have already started showing their level of adoration for the sector with billions in funding dollars, which, ironically, are pouring in as the investment community maintains a somewhat cautious approach to more traditional segments of the industry. The excitement for digital health goes beyond simply wanting to be part of the “next big thing,” though the investor adrenaline-rush factor certainly plays a role in the market’s high numbers. However, in the bigger picture, the interest is connected more to the changing nature of health care as a result of a convergence of come-of-age technology, aggressive cost-cutting measures, and the shifting of responsibility for patient health.

The dollar figures back up investor enthusiasm for the market, and 2014 was a recording-breaking year with more than $4.1 billion in funding going to 258 companies in the digital health care space, according to the Rock Health Funding Database, which provides one of the most accurate views of money coming into this market. In its year-end report for 2014, Rock Health found that the level of funding for the year represented 125% year over year growth from 2013, and the $4

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.